Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (NDAQ:ATXI)

Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

GlobeNewswire October 28, 2019

Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting

GlobeNewswire October 18, 2019

Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2019

Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors

GlobeNewswire August 1, 2019

Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

GlobeNewswire June 3, 2019

Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire May 13, 2019

Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors

GlobeNewswire April 30, 2019

Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire March 12, 2019

Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

GlobeNewswire February 11, 2019

Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Sogou Inc. (NYSE:SOGO)

GlobeNewswire January 19, 2019

Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

GlobeNewswire December 19, 2018

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI

PR Newswire December 12, 2018

Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire November 21, 2018

Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire November 14, 2018

InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

GlobeNewswire November 13, 2018

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2018

Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference

GlobeNewswire June 19, 2018

Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain

GlobeNewswire June 6, 2018

Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire May 3, 2018

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

GlobeNewswire March 28, 2018